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The Advisory Committee on Immunization Practices (ACIP) consists of medical and public health experts who
develop recommendations on vaccine use in the United States. The ACIP meets 3 times per year, and members
and Centers for Disease Control (CDC) staff present ﬁndings and discuss vaccine research, vaccine effectiveness
(VE) and safety, clinical trial results, and labeling/package insert information. Outbreaks of vaccine-preventable
diseases and vaccine shortages are also discussed. Nonvoting representatives from the American Academy of
Pediatrics and the Pediatric Infectious Diseases Society are present. The ACIP met on June 22–23, 2016 to
discuss proposed recommendations for inﬂuenza vaccination, for human papillomavirus (HPV) vaccine dosing
schedules, for the cholera vaccine (CVD 103-HgR), and for the use of MenACWY in human immunodeﬁciency
virus (HIV)-infected persons, as well as an overview of respiratory syncytial virus (RSV) vaccines, safety of
maternal tetanus, diphtheria, acellular pertussis (Tdap) immunization, and laboratory containment of
poliovirus type 2.
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INFLUENZA VACCINES
Background

The Inﬂuenza Working Group’s (WG) discussions have focused on new vaccines, vaccine safety updates for the
2015–16 season, and VE data for the 2015–16 season in
the United States. Dr Bruce Innis of GSK and Dr James
Mansi of Seqirus presented data on FluLaval and
FLUCELVAX, respectively. Dr Tom Shimabukuro of the
CDC provided an update on vaccine safety. Drs. Brendan
Flannery of the CDC and Chris Ambrose of MedImmune
gave a VE update for live-attenuated inﬂuenza vaccine
(LAIV). Dr Lisa Grohskopf of the CDC discussed the possible recommendations for the use of inactivated inﬂuenza
vaccine (IIV) and LAIV, and the ACIP voted on the 2015–
16 recommendations.
FluLavel Quadrivalent and FLUCELVAX Quadrivalent

Fluzone is currently the only IIV licensed for children ages
6–35 months. Other inﬂuenza vaccines have not been licensed in this young age group due to lack of immunogenic
noninferiority or unacceptable reactogenicity. FluLaval
Quadrivalent received US Food and Drug Administration
(FDA) approval in August 2013 for use in persons 3

years. Subsequent studies in children ages 6–35 months
demonstrated FluLaval Quadrivalent to be immunogenically noninferior to Fluzone Quadrivalent for all 4 strains
as determined by geometric mean titers (GMTs) and seroconversion response (SCR) 28 days after completion of
dosing. FluLaval met the Center for Biologics Evaluation
and Research’s SCR and seroprotective (SPR) criteria for
all strains except the SPR for B/Victoria. The vaccine was
immunogenically superior to Fluzone Quadrivalent for B
strains in 6- to 17-month-old children and all 6- to
35-month-old, unprimed children (children with no prior
history of inﬂuenza vaccination). Reactogenicity and safety
proﬁle between the 2 vaccines are similar. A supplemental
biologic license application (BLA) was submitted in
January 2016 to extend the indication for FluLavel
Quadrivalent to 6–35 months of age. The FDA will make
a decision by November 26, 2016.
FLUCELVAX Quadrivalent (cell culture IIV; ccIIV4), a
subunit inﬂuenza vaccine prepared from virus propagated
in a system where cells grow freely in suspension in culture
medium, is licensed for persons 4 years old. The ccIIV4
was noninferior to 2 ccIIV3 vaccines, each containing an
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alternate inﬂuenza B stain. The safety proﬁle between the
vaccines was similar. The ccIIV4 is thought to be a potential alternative to overcome issues associated with eggbased production, particularly in a pandemic.
Inﬂuenza Vaccine Safety

Inﬂuenza Vaccine Effectiveness

The US Flu VE Network consists of 5 sites, enrolling outpatients .6 months of age with acute respiratory illness
and cough 7 days duration. The network utilizes a testnegative design to determine VE in inﬂuenza reverse
transcription-polymerase chain reaction (RT-PCR)-conﬁrmed
patients. Receipt of at least 1 dose of any 2015–16 seasonal
inﬂuenza vaccine was assessed based on medical records, immunization registries, and by self-report. A total of 1341 of
7563 (18%) enrolled subjects were inﬂuenza positive. The majority, 772 (58%), were inﬂuenza A(H1N1)pdm09 (pH1N1)
positive. Inﬂuenza A H3N2 (6%), B/Yamagata (19%), and B/
Victoria (15%) were detected with the remainder being unsubtypeable A, unknown lineage B, or coinfection. Overall adjusted VE for any inﬂuenza virus was 47%. Adjusted VE for
speciﬁc vaccine strains across all ages was as follows:
pH1N1, 41%; H3N2, 45%; B/Yamagata, 55%; and B/
Victoria, 55%.
Of children ages 2–17 years, 411 of 2286 (18%) were
inﬂuenza RT-PCR positive during the 2015–16 season.
The majority (47%) were positive for pH1N1, followed
by H3N2 (3%), B/Yamagata (16%), B/Victoria (31%),
with the remainder unsubtypeable A, unknown lineage B,
or coinfection. In children, overall VE was 48% and 64%
in children 6 months–8 years and 9–17 years, respectively.

Figure 1. Inﬂuenza vaccine effectiveness by type/subtype, 2015–16.
Abbreviations: IIV, inactivated inﬂuenza vaccine; LAIV, live-attenuated inﬂuenza vaccine.
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No new safety concerns for IIV, LAIV4, ccIIV3, or recombinant inﬂuenza vaccine (RIV3) were identiﬁed from the
Vaccine Adverse Event Reporting System (VAERS).
Surveillance for the 2016–17 inﬂuenza season will include
monitoring for adjuvanted inﬂuenza vaccine (Fluad),
IIV4-ID (Fluzone Intradermal Quadrivalent), pregnancy
reports, and anaphylaxis reports in persons with a history
of egg allergy. Near real-time surveillance in the United
States in the 2015–16 season demonstrated an increase in
Guillain-Barré syndrome (GBS) rates after IIV with 7.25
cases per million IIV vaccines compared with an average
of 5.45 cases per million IIV vaccines from the prior 3 seasons. The Vaccine Safety Datalink (VSD) identiﬁed a significantly elevated relative risk for GBS of 3.67 with an
attributable risk after IIV3 of 2.6 additional cases per million doses administered. Further investigation, including
chart review of cases and adjustment for seasonality and
other confounders, is being performed. Guillain-Barré syndrome risk estimate appears to be consistent with that observed in some previous inﬂuenza seasons.

The VE for LAIV was signiﬁcantly lower than IIV, with no
effectiveness at all of LAIV for prevention of infection by
pH1N1 or B viruses (Figure 1). The LAIV recipients were
3.67-fold and 1.62-fold more likely to get pH1N1 and B,
respectively, compared with IIV recipients. Overall, IIV VE
in children aged 2–17 years was 63%, showing that the
poor effectiveness was limited to LAIV. A US Department
of Defense study of children aged 2–17 years also noted
no LAIV effectiveness against pH1N1, and a MedImmune
study had a VE estimate against pH1N1 that was not statistically signiﬁcant but with a higher point estimate. Both studies demonstrated signiﬁcant VE for IIV.
Data from the AstraZeneca Inﬂuenza Clinical Investigation
for Children study were presented. During 2015–16, children
ages 2–17 years from 8 US sites with inﬂuenza-like illness
were enrolled in an observational, test-negative design, similar to the CDC VE study. The VE for LAIV was 46% compared with an IIV VE of 65%. However, adjusted LAIV VE
estimates for pH1N1 and B crossed 0. In a MedImmune
study from the United Kingdom, LAIV4 VE was 57.6%,
but no speciﬁc VE for pH1N1 was reported.
Prior VE data were reported and reviewed for LAIV and
IIV VE. Since 2009, LAIV VE has been poor. In 2013–14,
studies from the US Flu VE Network, AstraZeneca, and
Department of Defense noted no signiﬁcant VE for LAIV
against pH1N1 despite signiﬁcant VE for IIV3 against
pH1N1. The reason for the poor LAIV VE is unknown, although hypotheses include the suboptimal performance of
the pH1N1 hemagglutinin vaccine component, potential
interference among viruses in the quadrivalent vaccine,
or reduced immunogenicity due to a population more highly vaccinated with LAIV in recent years. The FDA is

ACIP Update

concerned and is working with MedImmune to gather
more information; at this time, they have determined that
speciﬁc regulatory action is not warranted.
Working Group Recommendations and Advisory Committee
on Immunization Practices Discussion

HUMAN PAPILLOMAVIRUS VACCINES
Background

The WG reviewed evidence for a 2-dose HPV vaccine
schedule. Dr Allison Kempe, WG chair, reviewed background information on the 2-dose schedule presented at
the previous ACIP meeting and noted that a supplemental
BLA supporting a 2-dose schedule was submitted to the
FDA in early 2016. Dr Lauri Markowitz of the CDC reviewed data on duration of protection after HPV vaccination. Dr Marc Brisson of Laval University discussed
cost-effectiveness of a 2-dose vaccination schedule, and
Dr Sara Oliver of the CDC discussed HPV VE after
2-dose schedules. Dr Elissa Meites presented Grading of
Recommendations Assessment, Development, and
Evaluation (GRADE) for 2-dose schedules, and Dr Lauri
Markowitz reviewed the recommendation options.
Noninferiority and Maintenance of Antibody in a Two-Dose
Schedule

The WG reviewed data demonstrating noninferiority between a 2-dose schedule (0, 6 months or 0, 12 months)
in children aged 9–14 years compared with a 3-dose series
(0, 2, 6 months) in persons 15–26 year olds. Follow-ups
from bivalent (2vHPV) and quadrivalent HPV (4vHPV)
vaccine studies demonstrate maintenance of antibody responses for as long as 14 years. Waning antibody response
was not associated with loss of protection for HPV type 18.

Although long-term protection data are not available for
the 2-dose series, the 2-dose schedule for 2vHPV and
4vHPV seems to generate similar antibody kinetics in adolescents compared with a 3-dose schedule in women.
Cost-Effectiveness of a Two-Dose Schedule

Using a vaccine cost of $158 per 9-valent HPV (9vHPV)
administration, 2 doses must protect for more than 20
years for the third dose to be cost-ineffective. This was
not adjusted for a higher per-dose cost for the 2-dose series.
Therefore, cost-effectiveness depends on the relative duration of efﬁcacy of the 2- and 3-dose schedules, the additional vaccination coverage achieved through a reduced vaccine
schedule, and the cost per dose. A 2-dose schedule will provide similar population-level health beneﬁts as a 3-dose
schedule unless the 2-dose schedule provides a shorter
duration of protection and does not enable higher vaccination coverage. Conclusions are similar with the 4vHPV effectiveness and cost-effectiveness analyses in Canada and
the United Kingdom.
Human Papillomavirus Vaccine Effectiveness

Thirteen studies with VE data for the 2-dose schedule were
reviewed. Four studies included evaluations of 0- and
6-month intervals, with 3 of these reporting similar outcomes between a 2- and 3-dose series. All were post hoc
analyses of clinical trials. Ten studies found that 2 doses
were not as effective as 3 doses. However, all of these studies
were post-licensure effectiveness studies performed within
the setting of a recommended 3-dose schedule, so most of
the subjects received the HPV immunization at 0 and 1
month or 0 and 2 months, as opposed to 0 and 6 or 0 and
12 months. Persons receiving the 2-dose schedule were different from those receiving the 3-dose schedule in regards
to age, socioeconomic status, and timing of cervical screening, all factors that have implications on HPV exposure. The
GRADE for the 2-dose schedule is overall evidence type 3.
Working Group Recommendations

Draft recommendations were presented. New recommendations included a 2-dose schedule with the second dose
being administered 6 to 12 months after the ﬁrst dose.
For persons initiating the vaccine series after their 15th
birthday or immunocompromised persons of any age, the
WG is considering its recommendation for a 3-dose series
with a schedule of 0, 1–2, and 6 months. No vote was taken
by the ACIP at this meeting, although there was general
support for a 2-dose schedule. A vote will likely to place
at the October 2016 meeting.
CHOLERA VACCINE
Dr Karen Wong of the CDC provided an update on cholera
epidemiology, at-risk populations, the recently licensed
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The WG considered multiple different recommendations
with the goal of conveying that the latest data suggest
that IIV is more effective than LAIV against pH1N1 and
that VE for LAIV against AH3N2 and B viruses is uncertain. The WG noted that policy should encourage the use
of the most effective vaccine, and recommendations would
be interim for the 2016–17 season. It is expected that LAIV
represents 14 million (8%) of the total 171–176 million
doses of inﬂuenza vaccine. The WG recognized that not
recommending LAIV may impact school-based immunization programs, persons who refuse injectable vaccine, and
future evaluation of LAIV effectiveness.
The WG proposed 2 options: LAIV should not be used
or LAIV use should be limited. After lengthy discussion,
ACIP voted to approve the recommendation that LAIV
should not be used for the 2016–17 seasons based on
poor VE for the last 3 inﬂuenza seasons. The ACIP also approved removal of LAIV from Vaccines for Children (VFC)
coverage.
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vaccine, and the proposed recommendations for vaccine
use from the WG. There was discussion among the ACIP
members and others before a vote regarding the proposed
recommendations.
Background

Cholera Vaccine Update

The vaccine is a live-attenuated single-dose oral cholera
vaccine that protects against toxigenic Vibrio cholerae
O1. A previous formulation had formerly been licensed,
but after its removal from the US market, it was redeveloped as Vaxchora. The vaccine is immunogenic and protective against cholera challenge. The GRADE evidence
type is 2, with safety evidence type 2 and efﬁcacy evidence
type 1. Vibriocidal antibody response from the vaccine
ranged from 29% to 98% in children ages 3 months–17
years in 3 countries based on available data from the previous formulation. No systemic adverse events were noted
after the use of the older vaccine in the pediatric population. Cumulative shedding data of the new vaccine range
from 3.3% to 12.5% in 2 studies, although the new vaccine
was not isolated from stools of household contacts cultured
7 days postvaccination. The older vaccine was isolated in
,1% of household contacts 5 days postvaccination with
seroconversion of 3.7% of family contacts at 9 or 28
days. In challenge studies, VE of the new formulation
against severe (.3 liters) diarrhea was 90.3% at 10 days
and 79.5% at 3 months. The older formation had a VE
of approximately 100% against diarrhea of any severity
at 4–6 months. There are no data on reimmunization
with the new formulation.
Work Group Recommendations

Safe food and water precautions, proper sanitation, and
proper hygiene measures were reviewed as the primary

MENINGOCOCCAL VACCINES
Background

Dr Laura York of Pﬁzer gave an update on the new
MenB-FHbp (Trumemba) label, which allows for a
2-dose schedule, and Ms. Jessica MacNeil of the CDC
presented the WG discussions on the 2-dose schedule.
Dr Ismael Ortega-Sanchez of the CDC presented data
on the cost-effectiveness of MenACWY in HIV-infected
persons. Ms. Jessica MacNeil presented the WG’s considerations for the use of MenACWY in HIV-infected persons and the proposed recommendations. The ACIP
then voted on the use of MenACWY in HIV-infected
persons.
MenB-FHbp (Trumemba) Two-Dose Schedule

In April 2016, the FDA approved a 2-dose schedule (0, 6
months) for MenB-FHbp. This is in addition to the already
approved 3-dose schedule (0, 1–2, and 6 months) for
MenB-FHbp. The FDA recommended that the dosing
schedule should be based on risk of exposure and susceptibility to disease. The current ACIP recommendation going
into the meeting was a 3-dose series for MenB-FHbp and a
2-dose series for MenB-4C.
The WG reviewed immunogenicity data for MenBFHbp. Of the 2-dose schedules evaluated, the 0 and 6
months schedule had the highest percentage of responders
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The Cholera Vaccine WG was formed in August 2015.
Since the February 2016 meeting, the WG has reviewed
data in special populations, including pregnant and breastfeeding women, immunocompromised persons, and children. The WG has also reviewed data regarding shedding
and transmission of the vaccine strain and duration of protection. On June 10, 2016, CVD 103-HgR vaccine
(Vaxchora) was licensed by the FDA to prevent cholera
in adults, ages 18–64 years, traveling to cholera-affected
areas. Although cholera is rare in the United States, most
cases occur among travelers to affected areas, and an increase in cases in travelers from Haiti was recognized
after a Haitian epidemic in 2010. High-risk individuals include the following: travelers visiting friends and relatives;
long-term travelers; travelers who do not follow safe food,
water, and hygienic practices; and healthcare workers with
direct exposure to bodily ﬂuids from cholera patients.

preventive strategies against cholera infection. Travelers
with severe diarrhea should seek prompt medical attention
and rehydration therapy. The WG recommended that the
decision to vaccinate be based on the traveler’s risk of exposure and risk of severe outcomes if infected. Risk of exposure is increased in travelers unable to follow preventive
strategies while visiting friends and relatives in areas of active toxigenic V cholerae O1 exposure as well as healthcare
workers with direct contact with body ﬂuids from patients
with cholera. Travelers at risk of poor outcomes include
those without rapid access to rehydration and medical
care, low gastric acidity, blood type O, and travelers with
chronic medical conditions. The vaccine is anticipated to
cost $200–$300 and should be given 10 days before travel. The ACIP and others discussed the complexity of the
language describing the 2 groups; eg, does a patient have
to know their blood type to receive the vaccine? The
ACIP decided against specifying high-risk subpopulations
(those at high risk of exposure and those at risk of severe
outcomes) and voted to recommend use of the vaccine in
adults traveling to an area of active toxigenic V cholerae
O1 transmission as a category A recommendation. A pediatric study in children 2–18 years is planned to start next
year.

ACIP Update

Cost-Effectiveness of MenACWY and Rates of Meningococcal
Disease in Human Immunodeﬁciency Virus-Infected Persons

Cost per quality-adjusted life year (QALY) gained by recommending MenACWY in HIV-infected persons is approximately $723,000. This ﬁgure was compared with
various other vaccine recommendations and noted to
have a much higher cost per QALY. Routine vaccination
of HIV-infected persons against MenACWY, including primary series and periodic boosting, is costly due to low rates
of disease cases and deaths as well as the high cost of repeated boosting.
From 1995 to 2014, 62 cases of meningococcal disease
among HIV-infected persons, or 2% of total meningococcal cases, were reported in the Active Bacterial Core (ABC)
surveillance program. Disease was primarily due to
serogroups C, W, and Y. The relative risk of meningococcal
disease was 12.9 in HIV-infected persons meeting the
CDC/acquired immune deﬁciency syndrome (AIDS) surveillance case deﬁnition (referent to uninfected and
HIV-positive but not meeting AIDS case deﬁnition).
Meningococcal disease risk in HIV-infected persons compared with HIV-uninfected persons, previously presented
at the February 2016 meeting, was reviewed. There was
only 1 case of meningococcal disease among children
under 10 years of age recorded in the ABC data. In summary, HIV-infected adults and adolescents have an increased rate of meningococcal disease ranging from 5- to
24-fold. The risk of meningococcal disease in
HIV-infected persons increases with low CD4 count or
high viral load. The seroresponse to MenACWY-D conjugate vaccine is lower in HIV-infected adolescents than
healthy adolescents and HIV-infected 2- to 10-year-olds.
Immune response to the vaccine wanes rapidly although
an increased response occurs with boosting.

Work Group Recommendations

Only MenACWY conjugate vaccine recommendations
were discussed because disease in HIV-infected persons is
primarily due to serogroups C, W, and Y, and no safety
or immunogenicity data exist for serogroup B meningococcal vaccines in HIV-infected persons. Considerations for
the recommendation included the requirement of regular
booster doses because the risk of meningococcal disease
with HIV infection is lifelong. The WG, recognizing the
suboptimal vaccine response and duration of protection,
supported the inclusion of HIV-infected persons into the
group at increased risk of meningococcal disease. The
ACIP and liaisons discussed 2 policy options that differed
regarding the age, 2 months or 11 years, at which vaccination should begin. The pros of initiating vaccination at 2
months included harmonization with current ACIP recommendations for the use of the vaccine in asplenic- and
complement-deﬁcient patients, a low ﬁnancial and burdensome recommendation due to the small number of
HIV-infected children, a presumed increased risk of meningococcal disease similar to older children and adults, and
higher hSBA titers postvaccine in HIV-infected children
ages 2–10 years compared with HIV-infected adolescents.
The pros of initiating vaccine at age 11 years included decreasing the number of booster doses over a lifetime.
The ACIP reviewed both policy options and voted to approve the recommendation for routine receipt of
MenACWY in HIV-infected persons aged 2 months.
Additional recommendations include the use of a 2-dose
(0, 2 months) primary series with MenACWY in
HIV-infected persons aged 2 years who have not been
previously vaccinated and the use of a multidose schedule
for children aged ,2 years. HIV-infected persons previously
vaccinated with one dose of MenACWY should receive a
second dose at the earliest opportunity with an 8 week minimum interval between doses. Human immunodeﬁciencyinfected persons should receive booster doses every 3 years
if age ,7 years at previous dose and every 5 years if age 7
years at previous dose. The VFC coverage also was
approved.

HEPATITIS
The ACIP provided comprehensive recommendations for
hepatitis A in 2006 and for hepatitis B in 2005 and
2006. These recommendations will be updated in the
near future, with a revision to the hepatitis B statement expected by October 2016. Current WG considerations include hepatitis A disease burden, population protection,
catch-up vaccination for children 2–18 years, and
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with GMTs most similar to the 3-dose schedule. However,
GMTs and the proportion of subjects with a 4-fold rise in
human complement serum bactericidal assay (hSBA) titers
both were lower. Safety and tolerability are similar between
the 2- and 3-dose schedules, with injection site pain being
the most common adverse event. Policy options discussed
by the WG include a preference for the 3-dose schedule
for at-risk persons, which would include outbreaks, due
to early protection and maximization of the immune response. However, a preference for the 3-dose schedule in
healthy adolescents was also expressed. At the October
2016 ACIP meeting, data will be presented on antibody
persistence after the 2-dose schedule, evaluation of hSBA
data for MenB-FHbp and MenB-4C against US outbreak
strains, and the impact of MenB-FHbp on carriage
among college students.
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immunogenicity and safety of HEPLISAV-B (a 2-dose hepatitis B vaccine in adults).
RESPIRATORY SYNCYTIAL VIRUS VACCINES
Background

The current goal of the RSV Vaccine WG is to consider recommendations for the use of a vaccine in adults 60 years
old and those with underlying medical conditions.
Dr Lindsay Kim of the CDC presented an overview of
RSV and RSV vaccines.
Respiratory syncytial virus causes 177 000 hospitalizations
and 14 000 deaths annually. The goal of RSV vaccine development is to safely induce sufﬁcient immunity to protect
against serious RSV infections (eg, lower respiratory tract
infection [LRTI] and apnea in infants). Respiratory syncytial virus vaccine development has been complicated. A
formalin-inactivated vaccine tested in children in the
1960s had signiﬁcant unexpected adverse events. When
subsequently infected with RSV, seronegative vaccine recipients had more severe LRTI compared with vaccine nonrecipients; vaccine recipients had hospitalization rates of
80%, including 2 deaths, compared with 5% of controls.
This vaccine-enhanced disease syndrome in RSV-naive vaccine recipients is thought to be related to poor
vaccine-induced neutralizing antibody as well as a Th2 biased immune response with enhanced cytokine release
upon subsequent infection. Potential new vaccine strategies
include replicating or vectored vaccines, subunit vaccines,
and maternal immunization to protect young infants.
Novavax’s RSV fusion protein subunit nanoparticle vaccine will be the ﬁrst RSV vaccine considered for FDA licensure. Over the next 1–2 years, the RSV WG will assess the
epidemiology and burden of RSV in older adults, review
vaccine manufacturer presentations, consider correlates
of protection and immunogenicity, and assess costeffectiveness. Implementation considerations and a potential vote are anticipated in 2018.
TETANUS, DIPHTHERIA, ACELLULAR PERTUSSIS
VACCINE SAFETY DURING PREGNANCY
Background

Since October 24, 2012, ACIP has recommended the use of
Tdap during every pregnancy, irrespective of prior Tdap receipt, with optimal immunization timing between 27 and 36
weeks gestation. The ACIP acknowledged the need for enhanced monitoring and safety studies for Tdap given during
pregnancy. Dr Pedro Moro of the CDC presented data on
enhanced surveillance of Tdap vaccine safety in pregnancy
from VAERS. Dr Lakshmi Sukumaran of the CDC provided
data from the VSD on maternal vaccination and structural

Tetanus, Diphtheria, Acellular Pertussis Vaccine Safety from
the Vaccine Adverse Event Reporting System and Vaccine
Safety Datalink

The Tdap vaccination coverage has increased from 27% in
2014 to 42.1% in 2015. The VAERS surveillance from
October 2011 to June 2015 demonstrated no new or unexpected safety concerns among Tdap-immunized pregnant
women or their infants. A limited number of pregnancy reports with repeat Tdap doses have been received by
VAERS, and these will continue to be monitored by the
CDC. Data from the VSD suggest that maternal Tdap vaccination during pregnancy was not associated with an increased risk for birth defects.
Reactogenicity and Immunogenicity of Tetanus, Diphtheria,
Acellular Pertussis in Pregnant Women

The vaccine was well tolerated in pregnant women.
Moderate/severe injection-site pain occurred more frequently in pregnant than nonpregnant women, but the
rates were consistent with clinically reported rates and
did not lead to medical visits. Approximately one half of
women had received a prior Tdap, and rates of moderate/
severe reactions were similar between women who had and
had not received a prior Tdap. All women had signiﬁcantly
higher antigen-speciﬁc antibody titers after vaccination.
Timing of Tetanus, Diphtheria, Acellular Pertussis
Immunization During Pregnancy

The WG reviewed 3 studies that demonstrated equal or higher antibody concentrations among infants born to mothers
with second trimester Tdap vaccination compared with
third trimester vaccination. No differences in neonatal antibody titers were noted between mothers vaccinated in the
late second trimester and during the third trimester. In
February 2016, the United Kingdom’s Joint Committee on
Vaccination and Immunization recommended that maternal
Tdap vaccination be given as early as 16 weeks gestation but
after the mid-pregnancy ultrasound, generally approximately 18–21 weeks. The WG will review new data and current
guidance on Tdap vaccination in pregnant women. At the
October ACIP meeting, the timing of maternal Tdap vaccination will be summarized with a draft statement prepared.
LABORATORY CONTAINMENT OF POLIOVIRUS
TYPE 2
The last wild-type poliovirus type 2 and 3 cases occurred in
India in 1999 and in Nigeria in 2012, respectively. In 2016,
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birth defects in offspring. Dr Kathryn Edwards of
Vanderbilt University School of Medicine presented data
on the reactogenicity and immunogenicity of Tdap in pregnant women, and Dr Art Reingold, chair of the WG, provided an update from the WG.

ACIP Update

poliovirus was endemic in the United States, or when
OPV was in use).
VACCINE SUPPLY
Sanoﬁ Pasteur is experiencing a manufacturing delay of
diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus inﬂuenzae type b (DTaP-IPV/Hib)
(Pentacel) with a supply for only 70% of historical demand. Individual vaccines are in adequate supply, and resolution is expected during the second half of this year.
Merck is experiencing a shortage of preﬁlled syringes for
HPV, hepatitis B, and hepatitis A vaccines, with anticipation of availability in the second quarter of calendar year
2017. Vial formulations are available in adequate supply.
Up-to-the-minute information can be found at http://www.
cdc.gov/vaccines/vac-gen/shortages/.
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17 wild-type poliovirus type 1 cases occurred in 2 endemic
countries, Pakistan and Afghanistan. The World Health
Organization (WHO) Global Action Plan minimizes poliovirus facility-associated risk after type-speciﬁc eradication
of wild polioviruses and cessation of oral poliovirus vaccine (OPV) use. The goal of the program is not absolute
poliovirus containment but rather a major risk reduction.
It is a phased plan with containment of poliovirus type 2
being implemented ﬁrst in 2016. Laboratory containment
means destroying, and documenting, specimens by autoclave or incineration or transfer to an “essential” laboratory facility that works within an appropriate containment
space. The CDC is the largest WHO Global Polio
Reference Laboratory. In 2015–16, 9 US laboratories
reported possession of a wild-type or vaccine-derived poliovirus potentially infectious materials, and 8 US laboratories reported possession of OPV/Sabin potentially
infectious materials. It is likely that some laboratories
may not be aware of poliovirus containment and may be
unknowingly storing potentially infectious materials (for
example, frozen stool specimens from periods when
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